An independent data monitoring committee, following a safety review, recommended that a Phase 2 trial of BX004, Biomx’s experimental…
Articles by Andrea Lobo, PhD
The U.S. Food and Drug Administration (FDA) has cleared the start of the third part of a Phase 2 clinical…
Researchers have identified three groups of symptoms with interconnected severity — respiratory-energy, mood-gastrointestinal irritability, and pain-gastrointestinal abnormal motility — in…
All eligible cystic fibrosis (CF) patients in England can now receive Vertex Pharmaceuticals’ CF treatment Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), after…
More than a third of caregivers of children with cystic fibrosis (CF) reported delays in getting information about the…
The Cystic Fibrosis Foundation (CFF) has awarded $5 million to the Cleveland Clinic to continue as the biorepository coordinating…
The Clairity Ball — the hallmark annual event of Claire’s Place Foundation — is set to return to…
The events slated for this year’s Cystic Fibrosis Awareness Month aim to celebrate the accomplishments, milestones, and hopes of those…
Children and adolescents with cystic fibrosis (CF) treated with Kaftrio, marketed as Trikafta in the U.S., experienced increases…
Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) contributed to a reduction in pulmonary exacerbations requiring hospitalization between 2018 and 2022 among children…